Cangrelor

Description

Kengreal (cangrelor) is an intravenous antiplatelet medication that works by inhibiting platelet aggregation to reduce the risk of blood clots during certain heart procedures. It's supplied as a 50 mg lyophilized powder for injection by Chiesi USA, Inc., and was approved by the FDA in 2015. This information was generated using AI and is provided for informational and research purposes only.

Resources

Name Format Description Link
21 Access the FDA dataset for Cangrelor — ANDA 213551 submitted by Mylan Institutional LLC https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213551

Tags

  • fda
  • drug-safety
  • drug-information
  • prescription-drugs
  • drug

Topics

Categories